Cellectis
  • About
    Our mission
    Governance
    Partners
  • Science
    Our Genome Engineering Platform
    TALEN® Technology
    In-House Manufacturing
  • Pipeline
    Product Candidates
  • Investors
    IR Overview
    News
    • Press releases
    • Events and Webcasts
    Presentations
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    Corporate Governance
    • Board of Directors
    • Executive Committee
    • External Auditors
    • Governance Documents
    • General meetings
    Financial Information
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    Shareholders Services
    • IR Inquiries
    • IR FAQ
  • Careers
    Our culture
    Job opportunities
  • Contact us
LinkedinX FR
› Investors › Scientific presentations
  • About
    • Our mission
    • Governance
    • Partners
  • Science
    • Our Genome Engineering Platform
    • TALEN® Technology
    • In-House Manufacturing
  • Pipeline
    • Product Candidates
  • Investors
    • IR Overview
    • News
      • Press releases
      • Events and Webcasts
    • Presentations
      • Corporate presentations
      • Scientific presentations
      • Scientific publications
    • Corporate Governance
      • Board of Directors
      • Executive Committee
      • External Auditors
      • Governance Documents
      • General meetings
    • Financial Information
      • SEC filings
      • Financial statements
      • Voting Rights & Share Capital
      • Stock information
    • Shareholders Services
      • IR Inquiries
      • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
  • Contact us
FR
LinkedinX

Scientific presentations

All 2026 2025 2024 2023 2022 2021
10
Jun 2022
17:39 E.S.T.

Pre-Clinical Proof Of Concept Demonstrates Robust Activity Of UCART20x22 Dual CAR T-Cells For The Treatment Of B-Cell Malignancies – EHA 2022- Poster Presentation

Download the PDF file
10
Jun 2022
17:35 E.S.T.

Preliminary Results from the Flu/Cy/Alemtuzumab arm of the Phase I BALLI-01 Trial of UCART22- EHA 2022- Poster Presentation

Download the PDF file
16
May 2022
18:22 E.S.T.

Endowing Universal CAR T-cell with Immune-Evasive Properties Using TALEN® -Gene Editing- ASGCT 2022- Oral Presentation

Download the PDF file
11
Apr 2022
15:16 E.S.T.

UCART20x22: First allogeneic dual CAR T-cell therapy for the treatment of B-cell malignancies – AACR 2022 – Abstract

Download the PDF file
10
Apr 2022
20:41 E.S.T.

UCART20x22: First allogeneic dual CAR T-cell therapy for the treatment of B-cell malignancies – AACR 2022 – Poster Presentation

Download the PDF file

Posts pagination

← PREV 1 2

Scientific publications

Discover Cellectis' scientific publications

Learn more
cellectis

Clinical-stage biotech · Dual-listed on Nasdaq (CLLS) and Euronext Growth (ALCLS).
Paris · New York · Raleigh.

  • ABOUT
    • Our mission
    • Governance
    • Partners
  • SCIENCE
    • Our Genome Engineering Platform
    • TALEN® Technology
    • In-House Manufacturing
  • PIPELINE
    • Product Candidates
  • INVESTORS
    • Events
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    • Governance Documents
    • ESG report
    • Shareholders Meetings
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    • PDMR Notifications
    • IR Inquiries
    • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
© 2026 Cellectis — All rights reserved
  • Legal notice
  • Community Guidelines